{"id":"W3112144762","doi":"10.1093/neuonc/noaa215.211","title":"CTNI-45. A PHASE 1B/2 CLINICAL STUDY OF NAPABUCASIN IN COMBINATION WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH RECURRENT OR PROGRESSED GLIOBLASTOMA MULTIFORME (GBM)","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Bioactive Compounds and Antitumor Agents","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Calgary","funders":"","keywords":"Temozolomide; Medicine; Internal medicine; Tolerability; Phases of clinical research; Adverse effect; Oncology; Surgery; Gastroenterology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004223723,0.0003340485,0.0007970065,0.0001430472,0.0001439975,0.00001432387,0.0003230411,0.000307214,0.00007669353],"category_scores_gemma":[0.0005436005,0.0002391905,0.00007920567,0.0004976559,0.0003395119,0.0001420906,0.0001024781,0.0008635406,0.000009115875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001064369,"about_ca_system_score_gemma":0.0003058429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000893656,"about_ca_topic_score_gemma":0.0003648985,"domain_scores_codex":[0.9967068,0.001003277,0.0008958841,0.0006748632,0.0002411878,0.0004780054],"domain_scores_gemma":[0.9971283,0.001110559,0.0006513871,0.0001830972,0.0006278208,0.000298805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1893229,0.104537,0.5728469,0.0002624058,0.0004900942,0.0004592761,0.003650997,0.00005232246,0.007859595,0.00007666925,0.003154514,0.1172874],"study_design_scores_gemma":[0.3819382,0.4272194,0.0730667,0.0001214115,0.0008463511,0.00004604515,0.003117243,0.01934229,0.01190832,0.0000238256,0.08135502,0.001015227],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993385,0.00001672051,0.0000655335,0.001510113,0.0006732818,0.004061217,0.0001288878,0.00006072616,0.00009852969],"genre_scores_gemma":[0.9965557,0.00002776968,0.0003746501,0.00253586,0.0001174119,0.0002871713,0.00004939631,0.00004421376,0.000007755885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4997802,"threshold_uncertainty_score":0.9753907,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1544762611913571,"score_gpt":0.4754712240521156,"score_spread":0.3209949628607585,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}